| SARS‐CoV‐2‐positive specimens | |||||
|---|---|---|---|---|---|
| Characteristic | Specimens collected | SARS‐CoV‐2 antibody ELISA* | Immunofluorescent antibody † | Microneutralisation † | Crude seroprevalence (ELISA) |
| All participants | 1685 | 7 | 3 | 3 | 0.42% |
| State | |||||
| New South Wales | 462 | 3 | 0 | 0 | 0.65% |
| Victoria | 455 | 3 | 2 | 2 | 0.66% |
| South Australia | 348 | 0 | 0 | 0 | — |
| Queensland | 323 | 1 | 1 | 1 | 0.31% |
| Western Australia | 97 | 0 | 0 | 0 | — |
| Age group (years) | |||||
| 0–4 | 630 | 0 | 0 | 0 | — |
| 5–9 | 494 | 1 | 0 | 0 | 0.20% |
| 10–19 | 561 | 6 | 3 | 3 | 1.07% |
| Residential geographic classification | |||||
| Major cities | 1306 | 5 | 2 | 2 | 0.36% |
| Regional | 359 | 2 | 1 | 1 | 0.27% |
| Remote | 19 | 0 | 0 | 0 | — |
| Unknown | 1 | 0 | 0 | 0 | — |
| Sex | |||||
| Girls | 662 | 1 | 0 | 0 | 0.15% |
| Boys | 1023 | 6 | 3 | 3 | 0.58% |
| Indigenous status | |||||
| Indigenous | 90 | 0 | 0 | 0 | — |
| Non‐Indigenous | 1595 | 7 | 3 | 3 | 0.44% |
ELISA = enzyme‐linked immunosorbent assay; SARS‐CoV‐2 = severe acute respiratory syndrome coronavirus 2.
*
Positive titre: ≥ 0.9.
†
Positive titre: ≥ 10.